These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2979764)

  • 1. In vivo characterization of P388 leukemia resistant to mitomycin C.
    Rose WC; Huftalen JB; Bradner WT; Schurig JE
    In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
    Donenko FV; Sitdikova SM; Kabieva AO
    Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
    Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM; Goldenberg S; Gottesman MM; Hait WN
    Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK; Chitnis MP; Embrey WM; Gregory EB
    Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia].
    Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):201-9. PubMed ID: 1899547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
    Chandrasekaran B; Dimling J; Capizzi RL
    Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
    Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
    J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
    Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
    Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
    Lepri E; Menconi E; Barzi AM
    Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
    Ramu A; Fuks Z; Gatt S; Glaubiger D
    Cancer Res; 1984 Jan; 44(1):144-8. PubMed ID: 6690032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
    Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
    Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
    Shinoda H; Inaba M; Tsuruo T
    Cancer Res; 1989 Apr; 49(7):1722-6. PubMed ID: 2924316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
    Wilkoff LJ; Dulmadge EA
    J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.
    Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y
    Cancer Res; 1983 Jun; 43(6):2905-10. PubMed ID: 6850602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrotriazole AK-2123 enhances mitomycin C activity in mice bearing multidrug-resistant tumors.
    Goncharova SA; Rajewskaya TA; Konovalova NP; Kagiya TV
    J Chemother; 2001 Dec; 13(6):635-40. PubMed ID: 11806625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells.
    Willson JK; Long BH; Chakrabarty S; Brattain DE; Brattain MG
    Cancer Res; 1985 Nov; 45(11 Pt 1):5281-6. PubMed ID: 3931904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The radiosensitizer AK-2123 enhances sensitivity of MDR-tumors to Mitomycin C].
    Goncharova SA; Raevskaia TA; Konovalova NP; Kagiia VT
    Vopr Onkol; 2000; 46(2):202-8. PubMed ID: 10853422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.